Cannakeys

Unlocking the Science of Cannabis

N-Arachidonoyl Dopamine (NADA) Cannabinoid Research

N-Arachidonoyl Dopamine (NADA) Research Dashboard

6

Primary Studies

0

Related Studies

6

Total Studies

Clinical Studies

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

3

Animal studies

2

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 6 studies associated with N-Arachidonoyl Dopamine (NADA).

Here is a small sampling of N-Arachidonoyl Dopamine (NADA) studies by title:

  • Early-life N-arachidonoyl-dopamine exposure increases antioxidant capacity of the brain tissues and reduces functional deficits after neonatal hypoxia in rats
  • Cytotoxicity of Endogenous Lipids N-acyl Dopamines and Their Possible Metabolic Derivatives for Human Cancer Cell Lines of Different Histological Origin
  • Time-Dependent Vascular Effects of Endocannabinoids Mediated by Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
  • Opposite effects of anandamide and n‐arachidonoyl dopamine in the regulation of prostaglandin E2 and 8‐iso‐PGF2α formation in primary glial cells
  • Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)

Components of the N-Arachidonoyl Dopamine (NADA) Research Dashboard

  • Top medical conditions associated with N-Arachidonoyl Dopamine (NADA)
  • Proven effects in clinical trials for N-Arachidonoyl Dopamine (NADA)
  • Receptors associated with N-Arachidonoyl Dopamine (NADA)
  • Individual study details for N-Arachidonoyl Dopamine (NADA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - N-Arachidonoyl Dopamine (NADA)

Description of N-Arachidonoyl Dopamine (NADA)

NADA is an endocannabinoid that was first reported by researchers from Italy in the year 2000.

Other Names:

N-Arachidonoyl Dopamine

N-Arachidonoyl Dopamine (NADA) Properties and Effects

Hypothermia, Analgesia, Neuroprotective. NADA inhibits FAAH

N-Arachidonoyl Dopamine (NADA) Receptor Binding

CB1, NADA binds with TRPV1 with an EC50 of 50nM.
Top  

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.